Discovery of a Potent and Selective CDKL5/GSK3 Chemical Probe That Is Neuroprotective.

Authors:
Ong HW; Liang Y; Richardson W; Lowry ER; Wells CI and 11 more

Journal:
ACS Chem Neurosci

Publication Year: 2023

DOI:
10.1021/acschemneuro.3c00135

PMCID:
PMC10161233

PMID:
37084253

View on PubMed View on PMC View Publisher
Journal Information

Full Title: ACS Chem Neurosci

Abbreviation: ACS Chem Neurosci

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neurology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Antiaging Strategies and Remedies: A Landscape of Research Progress and Promise.
Tenchov R; Sasso JM; Wang X and 1 more (2024) - Transparency Score: 3/6
Characterization of Hair Metabolome in 5xFAD Mice and Patients with Alzheimer's Disease Using Mass …
Chang CW; Hsu JY; Lo YT and 5 more (2024) - Transparency Score: 4/6
Inhibition of Seizure-Like Paroxysms and Toxicity Effects of <i>Securidaca longepedunculata</i> Ext…
Moussavi N; van der Ent W; Diallo D and 4 more (2024) - Transparency Score: 4/6
Patients with Neurodegenerative Proteinopathies Exhibit Altered Tryptophan Metabolism in the Serum …
Kaleta M; Hényková E; Menšíková K and 7 more (2024) - Transparency Score: 3/6
Psychedelic-like Activity of Norpsilocin Analogues.
Sherwood AM; Burkhartzmeyer EK; Williamson SE and 2 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"The authors declare no competing financial interest."

Evidence found in paper:

"The Structural Genomics Consortium (SGC) is a registered charity (number 1097737) that receives funds from Bayer AG, Boehringer Ingelheim, the Canada Foundation for Innovation, Eshelman Institute for Innovation, Genentech, Genome Canada through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/McGill/KTH/Diamond, Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510], Janssen, Merck KGaA (aka EMD in Canada and USA), Pfizer, the São Paulo Research Foundation-FAPESP, and Takeda. Research reported in this publication was supported in part by the NC Biotechnology Center Institutional Support Grant 2018-IDG-1030, NIH U24DK116204, NIH 1R21NS112770-01A1, and NIH 1R44TR001916."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025